What Hemostasis does

Hemostasis, LLC is a privately held medical device manufacturer founded in 2006 and headquartered in Saint Paul, Minnesota. The company specializes in bleeding control and wound healing technologies, with a product portfolio spanning hemostat dressings, topical hemostatic powders, bone hemostats, intranasal splints, and a drug delivery micro-sponge. Its two core technology platforms are proprietary NOCC (N,O-carboxymethylated chitosan) chitosan polymers and 100% plant-based polysaccharide biopolymers, the latter designed to avoid animal-derived or bovine agents. Multiple products have been evaluated in published clinical and preclinical studies, including porcine femoral and acute liver bleeding models as well as sinus cavity applications, providing a degree of clinical substantiation typical of Class II/III surgical devices.

The company's commercial operations are organized around direct sales of FDA-registered, ISO 13485-certified medical devices to hospitals, surgical centers, and physician offices, primarily within ENT, trauma, and emergency care settings. U.S. federal law restricts these devices to sale by or on the order of a physician, shaping the company's go-to-market toward surgeon-centric engagement and physician-led product development partnerships. Revenue is generated through hardware sales of branded product lines (PosiSep, NexStat, BleedArrest, BoneSeal, NexFoam, NexPak, Accel, Vectra F), with the company also offering custom OEM medical device manufacturing supported by large-capacity freeze-drying capabilities. Pricing is not publicly disclosed, and the company claims a global market footprint while concentrating operational infrastructure in a single Minnesota facility with 11–50 employees.

Name

Hemostasis

Legal name

Hemostasis, LLC

Website

https://hemostasisllc.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Hemostasis, LLC is a privately held Minnesota-based medical device manufacturer that develops and sells proprietary chitosan-based and plant-based biopolymer hemostatic products, nasal splints, and wound healing devices directly to hospitals, surgical centers, and ENT specialists globally.

Ownership category

akta.pro rank

Product category

Surgical Hemostats and Wound Healing Medical Devices

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Hemostatic medical devices
• Chitosan wound dressings
• ENT surgical products
• Plant-based biopolymers
• Bone hemostat devices

Headquarters

HQ city

Saint Paul

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Hemostasis, LLC generates revenue through the sale of proprietary hemostatic medical devices and bleeding control products to hospitals, surgical centers, and healthcare providers. The company manufactures products directly and sells through direct sales channels to medical professionals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Hemostasis, LLC manufactures and sells a portfolio of proprietary hemostatic medical devices and wound healing products based on NOCC chitosan polymer and plant-based polysaccharide biopolymer platforms. The company's product line includes chitosan-based hemostat dressings/intranasal splints (PosiSep family), plant-based topical hemostat powders (NexStat, NexStat Plus, Accel), epistaxis foam sponges (BleedArrest ER), bone hemostats (BoneSeal), intranasal splints (NexFoam, NexPak X), and a drug delivery micro-sponge (Vectra F) for hospitals, surgical centers, and ENT specialists worldwide.

Product overview

Hemostasis, LLC is a medical device company that manufactures a comprehensive portfolio of bleeding control and wound healing technologies for the global medical industry. The product portfolio centers on two core technology platforms: Chitosan (specifically NOCC - N,O-carboxymethylated chitosan) and Biopolymers (plant-based polysaccharides). The product line includes: PosiSep® family of hemostat dressings and intranasal splints (PosiSep® X, PosiSep®, PosiSep® C & C2) using chitosan technology for ENT applications; NexStat® and NexStat® Plus topical hemostat powders using plant-based biopolymers for surgical bleeding control; BleedArrest® ER foam sponge for epistaxis treatment; NexFoam® intranasal splint and NexPak® X intranasal splint for post-surgical nasal cavity support; BoneSeal® bone hemostat for bone surface bleeding; Accel® absorbable hemostatic powder; and Vectra F™ drug delivery micro-sponge technology. The company serves multiple surgical markets including ENT, trauma, and cardiac surgery, offering both chitosan-based and plant-based hemostat solutions to address diverse clinical bleeding situations.

Differentiator

Problem solved

Functional benefit

Brands

• PosiSep: Chitosan-based hemostat dressing and intranasal splint technology
• NexStat
• NexStat Plus
• BleedArrest
• BoneSeal
• NexFoam
• NexPak
• Accel
• Vectra F

Products and services

• PosiSep®X BAM A hemostat dressing and intranasal splint constructed from the company's proprietary NOCC chitosan polymer technology, designed for placement in the sinus cavity to provide bleeding control and superior patient comfort.
• PosiSep®X Hemostat Dressing/Intranasal Splint A chitosan-based hemostat dressing and intranasal splint that conforms to sinus anatomy, expands after hydration with saline, and provides longer-term tissue separation (7-10 days). Targeted at ENT surgeons and hospitals performing sinus surgery.
• PosiSep® Hemostat Dressing/Intranasal Splint A faster-dissolving chitosan-based hemostat spacer that provides 2-3 days of tissue separation, constructed from NOCC chitosan polymer technology for ENT sinus cavity applications.
• PosiSep®C & C2 Chitosan-based hemostat dressing products for the ENT (ear, nose, throat) market, utilizing proprietary NOCC technology for bleeding control and sinus cavity support.
• Vectra F™ Drug Delivery Micro-sponge A drug delivery micro-sponge technology for targeted pharmaceutical delivery applications.
• NexPak®X Intranasal Splint A plant-based intranasal splint made from natural polysaccharide materials, used to prevent adhesions in the nasal and sinus cavity after surgery or trauma.
• Accel® Absorbable Hemostatic Powder An absorbable hemostatic powder technology for bleeding control during surgical procedures.
• NexStat® Topical Hemostat Powder An all-natural, plant-based polysaccharide hemostat powder in an easy-to-use applicator, cleared in the U.S. for topical surgical procedures such as FESS (Functional Endoscopic Sinus Surgery). Meets ISO 10993 biocompatibility requirements and naturally dissolves from the sinus cavity within about a week.
• NexStat® Plus Topical Hemostat Powder A topical dressing for the temporary treatment of moderate to severe bleeding wounds, specially formulated with more hydrophilic particles that absorb up to five times their volume, quickly dehydrating blood cells to limit and control bleeding.
• BleedArrest® ER Foam Sponge A quick and painless plant-based hemostatic foam sponge for the treatment of epistaxis (nosebleeds), utilizing innovative biopolymer technology. Designed for ENT offices and Emergency Rooms, stops problematic bleeding in seconds without pain.
• BoneSeal® Bone Hemostat An absorbable bone hemostat combining a hydroxyapatite matrix and other biosorbable polymers. Provides immediate and long-term hemostasis without immediately dissolving, and hydroxyapatite has been shown to promote bone growth during post-operative healing. Synthesized without animal tissue.
• NexFoam® Topical Hemostat Sponge An intranasal splint intended to minimize bleeding and edema and prevent adhesions between the septum and the nasal cavity. Constructed from a 100% plant-based polysaccharide sponge that dissolves naturally over 7-14 days or can be easily removed with gentle irrigation and aspiration.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Marine Polymer Technologies: Developer of chitosan-based hemostatic devices (e.g., SyvekPatch, RapidRHINO). Closely comparable to Hemostasis because both companies leverage proprietary chitosan technology for surgical hemostasis and wound care in overlapping clinical applications.
• MedTrade Products (Celox): Manufacturer of Celox chitosan-based hemostatic gauze and granules used in trauma, surgical, and emergency settings. Directly comparable to Hemostasis as a chitosan-focused hemostat specialist with similar plant/polysaccharide-derived technology.

Broad incumbents

• Baxter International: Markets Floseal, Tisseel, and other leading surgical hemostats across a wide range of surgical specialties. Comparable as a competitor in the same hemostat category, though Baxter operates at much larger scale and uses plasma-derived rather than chitosan/biopolymer technology.
• Ethicon (Johnson & Johnson): Surgical hemostat portfolio including Surgicel, Surgifoam, and Evicel competes directly with Hemostasis products in OR settings. Much larger incumbent with broader surgical portfolio and established surgeon relationships.
• Becton Dickinson (BD): Offers surgical hemostats and wound care products through its BD Surgery segment. Comparable as a broad medtech incumbent with overlapping surgical hemostasis offerings across hospital customers.
• Integra LifeSciences: Sells regenerative wound care matrices, skin substitutes, and surgical devices (e.g., Integra dermal matrix, DuraGen). Overlaps with Hemostasis' chitosan and biopolymer matrix technologies used in surgical hemostasis and healing.

Emerging players

• Arch Therapeutics: Develops AC5 self-assembling peptide hemostatic technology for surgical and trauma bleeding. Comparable as a small-cap, niche hemostat innovator competing in similar surgical and wound care applications.
• Cohera Medical: Focused on surgical adhesives and sealants (e.g., TissuGlu). Adjacent competitor to Hemostasis in the surgical bleeding control and tissue management space, though addressing different mechanism (adhesion vs. hemostasis).
• Biom'Up (HEMOBLAST Bellows): Specialty hemostat company marketing HEMOBLAST collagen-based powder for surgical bleeding. Comparable as a focused, smaller-scale hemostat specialist competing in similar surgical bleeding control indications.
• Z-Medica (QuikClot): Manufactures kaolin and chitosan-based QuikClot hemostatic dressings for trauma, emergency, and surgical use. Comparable to Hemostasis in hemostat mechanism and clinical applications, particularly in bleeding control and wound management.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hemostasis-llc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemostasis